Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 1.00 |
| ▸ | CA1 | P00915 | 14/20 | 1.00 |
| ▸ | CA9 | Q16790 | 14/20 | 1.00 |
| ▸ | CA12 | O43570 | 13/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548435 | 0.85 | CA2 (1.00) | CA2CA1CA9CA12SCN2A | |
| SCHEMBL20735193 | 0.85 | ALDH1A1 (0.82) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL17620194 | 0.81 | CA1 (0.68) | CA2CA1CA9CA12SCN2A | |
| SCHEMBL19429344 | 0.80 | CA2 (0.67) | CA2CA1CA9CA12SCN2A | |
| SCHEMBL28565249 | 0.80 | ALDH1A1 (0.70) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL20735205 | 0.80 | ALDH1A1 (0.74) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL20735204 | 0.80 | ALDH1A1 (0.74) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL18347260 | 0.79 | CA2 (0.87) | CA2CA1CA9CA12SCN2A | |
| SCHEMBL299841 | 0.78 | ALDH1A1 (0.71) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL25335143 | 0.77 | ALDH1A1 (0.70) | CA2CA1CA9CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685785-B2 | Methods and antibodies for modulation of immunoresponse | Ascendo Biotechnology, Inc. (KY) | 2023-06-27 | — | — | US | disclosed |
| EP-3194368-B1 | BENZO-HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | MACKAY MEDICAL FOUND THE PRESBYTERIAN CHURCH IN TAIWAN MACKAY MEMORIAL HOSPITAL (TW) | 2020-12-23 | — | — | EP | disclosed |
| US-20200339557-A1 | BENZO-HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | MACKAY MEDICAL FOUNDATION THE PRESBYTERIAN CHURCH IN TAIWAN MACKAY MEMORIAL HOSPITAL (TW) | 2020-10-29 | — | — | US | disclosed |
| US-20170283408-A1 | BENZO-HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | Lu, Yen-Ta (TW) | 2017-10-05 | — | — | US | disclosed |
| WO-2016197974-A1 | METHODS AND ANTIBODIES FOR MODULATION OF IMMUNORESPONSE | LU YEN-TA (CN) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016041511-A1 | BENZO-HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | LU YEN-TA (CN) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339557-A1 | BENZO-HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | CD274, PDCD1, PDCD1LG2 | CA2 2201/4885CA1 2827/4885CA9 966/4885 |
| US-20170283408-A1 | BENZO-HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | CD274, PDCD1, PDCD1LG2 | CA2 2201/4885CA1 2827/4885CA9 966/4885 |
| US-11685785-B2 | Methods and antibodies for modulation of immunoresponse | CD47, CD274, CD69 | CA2 4720/4885CA1 3668/4885CA9 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.